No Data
No Data
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Express News | Climb Bio Inc - Enters Technology Transfer and License Agreement With Mabworks
Climb Bio Signs Deal With Beijing Mabworks Biotech to Develop Antibody for IgA Nephropathy
Climb Bio To Make Upfront Cash Payment Of $9M To Mabworks Plus Certain Additional Payments Upon Achievement Of Specified Milestones
Climb Bio Enters Exclusive License Deal With Mabworks For Rights To Develop, Commercialize MIL116 (Now CLYM116) Monoclonal Antibody, In Territory Outside China